Detalhe da pesquisa
1.
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
Mult Scler
; 28(6): 910-924, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34605319
2.
Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
BMC Neurol
; 20(1): 364, 2020 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33023488
3.
Humoral Response to SARS-COV-2 Vaccination in Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Real-World Study.
Neurol Ther
; 13(1): 153-164, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38097868
4.
Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
Neurol Ther
; 12(6): 2177-2193, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37861931
5.
Treatment with natalizumab during pregnancy in multiple sclerosis: The experience of implementing a clinical practice protocol (NAP-30).
Mult Scler Relat Disord
; 66: 104038, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35870370
6.
Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study.
Neurol Ther
; 11(3): 1101-1116, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35524037
7.
Consensus on early detection of disease progression in patients with multiple sclerosis.
Front Neurol
; 13: 931014, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35968319
8.
Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder.
J Pers Med
; 12(5)2022 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35629165
9.
Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.
Mult Scler Relat Disord
; 63: 103805, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35512501
10.
Quantifying the patient´s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire.
PLoS One
; 16(7): e0255317, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34324586
11.
Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder.
Patient Prefer Adherence
; 15: 713-719, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33880015
12.
Generation of RRMS and PPMS specific iPSCs as a platform for modeling Multiple Sclerosis.
Stem Cell Res
; 53: 102319, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33894548
13.
SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.
Neurol Neuroimmunol Neuroinflamm
; 8(5)2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34168057
14.
Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
Mult Scler Relat Disord
; 44: 102311, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32593958
15.
Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study.
Mult Scler Relat Disord
; 31: 157-164, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31005729
16.
Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Mult Scler Relat Disord
; 26: 211-218, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30273841
17.
Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study.
Mult Scler Relat Disord
; 17: 107-115, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-29055438
18.
Capillary leak syndrome in neuromyelitis optica treated with rituximab.
Mult Scler Relat Disord
; 16: 22-23, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28755680
19.
Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus.
Neurol Neuroimmunol Neuroinflamm
; 3(3): e225, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27144216
20.
Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).
Rev Neurol
; 59(8): 371-9, 2014 Oct 16.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-25297480